Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world study of camrelizumab plus apatinib ± chemotherapy in advanced gastric cancer
ChiCTR2000034921Phase 4Not yet recruiting
- Sponsor
- First Affiliated Hospital of Anhui Medical University
- Start
- Sep 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of camrelizumab in gastric cancer (GC), sponsored by First Affiliated Hospital of Anhui Medical University. Primary endpoint: Progression-free survival. Planned start Sep 2020; status: not yet recruiting.
02
Drugs
camrelizumab
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on ChiCTR2000034921.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000034921.